Welcome to our dedicated page for PMV Pharmaceuticals SEC filings (Ticker: PMVP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
PMV Pharmaceuticals filings document a clinical-stage precision oncology company focused on small molecule therapies targeting p53. The company’s Form 8-K reports disclose operating results, financial condition updates, Regulation FD materials, and rezatapopt clinical disclosures from the PYNNACLE study in tumors with a TP53 Y220C mutation.
Proxy materials describe annual meeting matters, board composition, stockholder voting procedures, and governance practices. The filing record also identifies PMV’s Nasdaq-listed common stock and includes risk and forward-looking-statement disclosures tied to drug development, regulatory pathways, capital resources, and clinical-stage biotechnology operations.
PMV Pharmaceuticals, Inc. reported continued operating losses for the quarter and six months ended June 30, 2026 while advancing its lead oncology candidate, rezatapopt. Net loss was $18.1 million for the quarter and $36.1 million for the first half of 2026. Cash, cash equivalents, and marketable securities totaled $79.4 million at June 30, 2026, with management estimating this will fund planned operations only through the second quarter of 2027 and disclosing substantial doubt about its ability to continue as a going concern.
Research and development expenses were $30.0 million for the first half, primarily related to rezatapopt and the Phase 2 pivotal PYNNACLE trial. The FDA granted Orphan Drug Designation in March 2026 for rezatapopt in TP53 Y220C positive ovarian, fallopian tube, and primary peritoneal cancers, and enrollment of platinum-resistant/refractory ovarian cancer patients for the primary analysis has been completed. The company plans to seek accelerated approval with an initial NDA submission targeted for the first quarter of 2027.
PMV Pharmaceuticals reported second quarter 2026 results and a key clinical milestone for its lead asset rezatapopt. Enrollment for the primary analysis of platinum-resistant/refractory ovarian cancer patients in the Phase 2 monotherapy portion of the registrational PYNNACLE trial has been completed. The company plans to submit a New Drug Application for rezatapopt for platinum-resistant/refractory ovarian cancer in the first quarter of 2027 and notes existing Fast Track and Orphan Drug Designations.
PMV Pharma had $79.4 million in cash, cash equivalents and marketable securities as of June 30, 2026, and expects this to fund operations through the second quarter of 2027. For the quarter, net loss was $18.1 million versus $21.2 million a year earlier, driven mainly by lower contract research organization and finance support costs. Research and development expenses were $14.7 million compared with $18.4 million, and general and administrative expenses were $4.2 million compared with $4.5 million, reflecting cost reductions as the company advances its precision oncology pipeline targeting TP53 Y220C mutations.
Sio Capital Management, LLC, a Delaware investment adviser, reports beneficial ownership of 2,634,137 shares of PMV Pharmaceuticals, Inc. common stock as of June 30, 2026. This represents 4.94% of the class, based on 53,331,766 shares of common stock outstanding as of May 12, 2026.
Sio has shared voting and dispositive power over all 2,634,137 shares and no sole voting or dispositive power. The shares are held by various client funds for which Sio is investment adviser, with oversight by Sio GP, LLC, and control relationships involving Michael Castor, whose beneficial ownership is expressly disclaimed.
Item 5 states that the reporting person’s holdings constitute 5 percent or less of the issuer’s outstanding common stock.
ArrowMark Colorado Holdings, LLC reports beneficial ownership of 1,959,579 shares of PMV Pharmaceuticals, Inc. common stock, representing 3.67% of the class as of 06/30/2026.
The filing amends a Schedule 13G and states ArrowMark has sole voting and sole dispositive power over all 1,959,579 shares.
PMV Pharmaceuticals director Laurie Stelzer received a grant of stock options to acquire 42,000 shares of common stock. The options have an exercise price of $1.19 per share and expire on June 4, 2036. All 42,000 options vest on the earlier of June 4, 2027 or the date of the company’s next annual stockholder meeting. Following this award, Stelzer holds 42,000 options directly, reflecting a compensation-related grant rather than any open-market share purchase or sale.
PMV Pharmaceuticals, Inc. director Arnold J. Levine received a grant of stock options covering 42,000 shares of Common Stock at an exercise price of $1.1900 per share. These options expire on June 4, 2036 and vest on the earlier of June 4, 2027 or the issuer's next annual meeting of stockholders, leaving him with 42,000 options following the grant.
PMV Pharmaceuticals director Carol Giltner Gallagher reported option grants and internal transfers involving 42,000-share stock options. She received a stock option for 42,000 shares of common stock at an exercise price of $1.19 per share, expiring on June 4, 2036.
According to a footnote, these options vest on the earlier of June 4, 2027 or the issuer’s next annual meeting of stockholders. The filing also shows bona fide gifts moving options covering a total of 84,000 underlying shares, including a transfer to The Gallagher Revocable Trust dated May 10, 2011, for which she serves as trustee. These are non-market, gift and grant transactions rather than open-market buys or sells.
PMV Pharmaceuticals director Kirsten Flowers received a stock option grant covering 42,000 shares of common stock. The options have an exercise price of $1.19 per share and expire on June 4, 2036. These options vest on the earlier of June 4, 2027 or the date of the company’s next annual stockholder meeting.
PMV Pharmaceuticals director Charles M. Baum received a grant of stock options covering 42,000 shares of common stock. The options have an exercise price of $1.19 per share and expire on June 4, 2036. They vest on the earlier of June 4, 2027 or the company’s next annual stockholder meeting. Following this award, Baum holds 42,000 stock options directly.
PMV Pharmaceuticals, Inc. reported the results of its 2026 virtual annual meeting of stockholders. Stockholders elected two Class III directors: David H. Mack, Ph.D. received 15,693,907 votes for and 6,248,461 withheld, while Laurie Stelzer received 11,261,111 votes for and 10,681,257 withheld. Each will serve until the 2029 annual meeting, subject to earlier death, resignation or removal.
Stockholders approved, on a non-binding advisory basis, the compensation of the company’s named executive officers, with 15,015,578 votes for, 6,468,718 against, 458,072 abstentions and 6,975,412 broker non-votes. They also ratified the selection of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, by 28,379,108 votes for, 536,302 against and 2,370 abstentions.